In the ongoing open-label extension study, patients continuously treated with ZEPOSIA up to 6 yearsa had an ARR of 0.0932
A relapse was defined as the occurrence of new or worsening neurological symptoms persisting for more than 24 hours attributable to MS and immediately preceded by a relatively stable or improving neurological state of at least 30 days.3,4
*DAYBREAK is an ongoing OLE trial that enrolled participants from multiple randomized phase 1, 2, or 3 studies, including SUNBEAM and RADIANCE, and is presented as an interim analysis with a data cutoff of February 1, 2022. Endpoints were analyzed descriptively.2,5,6
aAt data cutoff (February 1, 2022), mean (range) continuous ozanimod 0.92 mg exposure in DAYBREAK was 56.4 (0.03-74.7) months.2
bStudy period includes DAYBREAK Day 1 through last treatment date or the data cutoff date of December 20, 2019.5
cAt data cutoff date of February 2, 2021.6
Proven Superior vs Avonex in Reducing Lesions Across All Secondary Measures of MRI Activity1
In the 1-year SUNBEAM study, brain MRIs were performed at baseline, Month 6, and Month 12.3,4
In the 2-year RADIANCE study, brain MRIs were performed at baseline, Month 12, and Month 24.3,4
9 of 10 Patients Showed No Confirmed 3-Month
Disability Progression1
92.4%
vs 92.2% For Avonex Showed No Confirmed
3-Month Disability Progression
POOLED ANALYSIS
92.4% vs 92.2%
For Avonex Showed No Confirmed
3-Month Disability Progression
Statistical significance was not reached for the pooled CDP.
7.6% of patients treated with ZEPOSIA (n=67/880) experienced 3-month confirmed disability progression (CDP), as measured by EDSS, similar to Avonex (7.8%; n=69/889) (P=NS)1,4
CDP was defined as at least a 1-point increase from baseline EDSS confirmed after 3 months and after 6 months. CDP was prospectively evaluated in a pooled analysis from the SUNBEAM and RADIANCE studies.
EDSS=Expanded Disability Status Score; NS=nonsignificant.